calendar
337 catalysts · 4,110 phase readout · 2,205 8k filing · 282 earnings · 172 phase 2 completion · 110 drug shortage · 73 phase 1 completion
next 91 dayslessmore
MonWedFri
337 catalysts · 4,110 phase readout · 2,205 8k filing · 282 earnings · 172 phase 2 completion · 110 drug shortage · 73 phase 1 completion
Sponsor: MANKIND PHARMA. Form: SOLUTION/DROPS. Route: OPHTHALMIC
Sponsor: RK PHARMA. Form: TABLET. Route: ORAL
Sponsor: REGENERON PHARMACEUTICALS. Form: INJECTABLE. Route: INJECTION
NS grant. $633,378. PI: Alba Miranda Azola
AI grant. $88,250. PI: Jennifer Lynn Hyde
AI grant. $440,211. PI: Julie Dunning Hotopp
ES grant. $605,091. PI: Yike Shen
NS grant. $429,000. PI: NAGI G AYAD
AI grant. $161,244. PI: TERESA GIL GIL
CA grant. $415,623. PI: STEPHEN J KADLECEK
AI grant. $267,000. PI: Qianxia Zhang
DK grant. $769,882. PI: Cary Ragan Boyd-Shiwarski
NR grant. $3,480,544. PI: Michelle Trivedi
ES grant. $795,869. PI: Sean M Harris
AI grant. $660,723. PI: Hongyan Guo
AI grant. $843,182. PI: Christopher F Basler
AT grant. $788,967. PI: ADAM L. Halberstadt
Sponsor: EXTROVIS. Form: SOLUTION. Route: INTRAVENOUS
Sponsor: NOVARTIS PHARMS CORP. Form: INJECTABLE. Route: INJECTION
Sponsor: NOVARTIS PHARMS CORP. Form: INJECTABLE. Route: INJECTION
Sponsor: NOVARTIS PHARMS CORP. Form: INJECTABLE. Route: INJECTION
Sponsor: NOVARTIS PHARMS CORP. Form: INJECTABLE. Route: INJECTION
Sponsor: QUAGEN. Form: SYRUP. Route: ORAL
Sponsor: YICHANG HUMANWELL. Form: TABLET, EXTENDED RELEASE. Route: ORAL
Sponsor: GLENMARK SPECLT. Form: CREAM. Route: TOPICAL
Sponsor: MARKSANS PHARMA. Form: CAPSULE, DELAYED RELEASE. Route: ORAL
Sponsor: GLENMARK PHARMS LTD. Form: TABLET, FOR SUSPENSION. Route: ORAL
Sponsor: GLENMARK PHARMS LTD. Form: TABLET, FOR SUSPENSION. Route: ORAL
Sponsor: IMPAX LABS. Form: CAPSULE. Route: ORAL
Sponsor: IMPAX LABS. Form: CAPSULE. Route: ORAL
AI grant. $209,758. PI: Paul K Drain
AT grant. $601,259. PI: Ashley E. Mason
NS grant. $568,920. PI: Theresa Currier Thomas
CA grant. $496,357. PI: DANIEL J BRAT
AT grant. $170,640. PI: Julia E. Hooker
AI grant. $210,302. PI: William Evan Johnson
DK grant. $231,000. PI: Roger D. Cone
NS grant. $230,562. PI: Thuy Nguyen
ES grant. $117,747. PI: Rebecca Sugrue
Sponsor: AUROBINDO PHARMA LTD. Form: TABLET. Route: ORAL
Therapy area: Infectious Disease. Indication: Pulmonary Tuberculosis
Sponsor: ACCORD HLTHCARE. Form: TABLET, EXTENDED RELEASE. Route: ORAL
Sponsor: AUROBINDO PHARMA. Form: CAPSULE. Route: ORAL
Anticipated earnings call for ACME UNITED CORP ($ACU).
Anticipated earnings call for Sanofi ($SNY).
Therapy area: Infectious Disease, Respiratory. Indication: Asthma, Influenzavirus A Infections, Influenzavirus B Infections
Therapy area: Gastrointestinal, Infectious Disease, Oncology. Indication: Acral Lentiginous Melanoma, Adenocarcinoma Of The Gastroesophageal Junction, Adenoid Cystic Carcinoma (ACC), Adrenocortical Carcinoma (Adrenal Cortex Cancer), Anaplastic Thyroid Cancer, Bile Duct Cancer (Cholangiocarcinoma), Bladder Cancer, Breast Cancer, Colorectal Cancer, Cutaneous Squamous Cell Carcinoma (cSCC), Endometrial Cancer, Ependymoma, Epithelial Ovarian Cancer, Esophageal Squamous Cell Carcinoma (ESCC), Ewing S
Therapy area: Oncology, Undisclosed. Indication: Lung Cancer, Solid Tumor, Unspecified Rare Disease
Therapy area: Dermatology. Indication: Diabetic Foot Ulcers
Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)